NCT05812807 2026-03-04Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus PembrolizumabAlliance for Clinical Trials in OncologyPhase 3 Recruiting1,295 enrolled